Phase 1 Lymphoma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Your cancer can be measured or detected on scans at the time you enter the study
- You have been diagnosed with one of the following blood cancers, confirmed by a tissue sample (biopsy): Diffuse large B-cell lymphoma (DLBCL), grade 3b follicular lymphoma, or lymphoma that has transformed from follicular lymphoma — and you have already tried at least 2 previous treatments
- You have follicular lymphoma (grades 1 through 3a) that needs treatment, and you have already tried at least 2 previous treatments
- You have a specific type of T-cell lymphoma (including angioimmunoblastic type or related subtypes) that has come back or stopped responding to at least 1 previous treatment
- You have high-grade B-cell lymphoma that has come back or stopped responding to at least 2 previous treatments
- You are generally able to carry out daily activities with little to no limitation (confirm with trial site what this means for your situation)
Who may not be able to join:
- Your lymphoma has spread to your brain or spinal cord, or it did in the past and has not been fully treated and clear for at least 12 months
- You have had a stem cell transplant using your own cells within the last 60 days, or a transplant using someone else's cells within the last 90 days
- You have received CAR T-cell therapy or a similar T-cell-based treatment within the last 4 weeks
- You have had major surgery or a serious physical injury within the last 4 weeks
- You have a significant ongoing medical condition, an active or uncontrolled infection, or abnormal lab results that would make it unsafe for you to participate (confirm with trial site)
- You are currently pregnant or breastfeeding
- You have a condition that affects how your body absorbs medication (confirm with trial site)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
5 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Number of participants experiencing adverse events (AEs) that meet protocol-defined dose-limiting toxicity (DLT) criteria following administration of TLN-121 alone or in combination with TLN-254.; Incidence and Severity of Treatment-Emergent Adverse Events (TEAEs) and Treatment-Related Adverse Events (TRAEs); Clinically significant ECG QT Interval from baseline in safety laboratory test results, assessed as per NCI CTCAE v5.0; Clinically significant laboratory abnormalities from baseline in safety laboratory test results, assessed as per NCI CTCAE v5.0
Can't join this trial?
Data last synced from ClinicalTrials.gov: 2 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.